Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, February 23, 2023
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
Paul Choi Maintained (VIR) at Strong Buy with Increased Target to $53 on, Feb 23rd, 2023
Paul Choi of Goldman Sachs, Maintained "Vir Biotechnology, Inc." (VIR) at Strong Buy with Increased Target from $41 to $53 on, Feb 23rd, 2023.
Paul has made no other calls on VIR in the last 4 months.
There are 4 other peers that have a rating on VIR. Out of the 4 peers that are also analyzing VIR, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Michael Ulz of "Morgan Stanley" Upgraded from Sell to Hold and Increased Target to $30 on, Friday, January 27th, 2023
These are the ratings of the 3 analyists that currently disagree with Paul
- Roanna Ruiz of "SVB Leerink" Maintained at Buy with Decreased Target to $43 on, Friday, January 27th, 2023
- Andrew Galler of "Morgan Stanley" Maintained at Sell with Increased Target to $18 on, Friday, November 4th, 2022
- Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $32 on, Friday, November 4th, 2022
